

MAR 10 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

10/628,841

Filing Date

July 28, 2003

First Named Inventor

Brett F. Monia

Art Unit

1635

Examiner Name

Jon Benjamin Ashen

Attorney Docket Number

RTS-0191US.C1

**ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)



Reply to Missing Parts/Incomplete Application



Reply to Missing Parts under 37 CFR 1.52 or 1.53



Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s)

Landscape Table on CD



After Allowance Communication to TC



Appeal Communication to Board of Appeals and Interferences



Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)



Proprietary Information



Status Letter



Other Enclosure(s) (please identify below):

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Isis Pharmaceuticals, Inc.

Signature

Printed name

Colleen J. McKleaman, PhD

Date

March 10, 2005

Reg. No.

48,570

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Jamie L. Toupal

Date

March 10, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**RECEIVED**  
**CENTRAL FAX CENTER**

MAR 10 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney Docket No.: **ISPH-0753 (ISIS No RTS-0191US.C1)**

Inventors: **Brett P. Monia, et al.**

Serial No.: **10/628,841**

Filing Date: **July 28, 2003**


Examiner: **Jon Benjamin Ashen**

Customer No.: **32,862**

Group Art Unit: **1635**

Title: **Antisense modulation of Inhibitor-Kappa B Kinase-Gamma expression**

**Certificate of Facsimile Transmission**  
I hereby certify that this paper is being facsimile  
transmitted to the Patent and Trademark Office to  
facsimile number 703-872-9306 on:  
March 10, 2005

  
\_\_\_\_\_  
Jamie L. Fougal  
Commissioner for Patents  
Alexandria, VA 22313

**Reply under 37 C.F.R. § 1.111**

Dear Examiner Ashen:

This is a reply to the Office Action mailed February 10, 2005 setting a one (1) month period for response. Please enter the following amendments and remarks into the record.

The **Amendments to the Claims** are reflected in the listing of claims which begins on page 2.

Remarks begin on page 4.